LN-229 In Vitro XTT Assay (Cell Viability)

This assay is to provide LN-229-based In Vitro XTT Assay (Cell Viability) to accelerate our client's oncology projects. The assay will be customized according to the specific requirements. Please contact our scientists to discuss more details.

LN-229

Human

The LN-229 cell line was established in 1979 from cells taken from a patient with right frontal parieto-occipital glioblastoma [PubMed. 10416987].

Glioblastoma

Oncology

In Vitro XTT Assay (Cell Viability)

LN-229-cell based In Vitro XTT Assay (Cell Viability)

Apart from the MTT tetrazolium, other tetrazolium compounds such as XTT (2,3-bis (2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide) can also generate formazan upon reduction by oxidoreductase or dehydrogenase. Unlike the normal MTT assay, assays with these regents (MTS, XTT and WST) do not require formazan solubilization step as solubilization occurs in the cell medium itself. Therefore, XTT, WST and MTS reagents can be used to assay viability of cells, which do not require a surface to attach.

XTT (2,3-bis (2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide) Assay

Cell Viability/Cytotoxicity and Antiproliferative Assays

Uncontrolled proliferation is one of the main features of cancer cells. Cell-based in vitro assays are employed to determine whether test molecules possess direct cytotoxic/antiproliferative effects in cancer cells.

Cell Viability Assay

Cell-based Viability Assays Based on Cellular Enzymes and Proteins